Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04216576

A Study of the Use of Text Message Reminders to Take Palbociclib

The purpose of this study is to find out whether it is feasible (acceptable to participants) to use a smartphone app to send text message reminders to take palbociclib, and whether these reminders are effective at helping people remember to take palbociclib according to the treatment schedule.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance)
  • >/= 18 years of age
  • Able to speak, read and write English
  • Willingness and ability to send and receive text messages with intervention app
  • Own a mobile telephone "smartphone" with text messaging capabilities. Only iPhone or Android operating systems support OhMD Application
  • Criteria applicable for both Control and Intervention groups
  • Flip-phones do not support OhMD Application and thus ineligible to participate
  • Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex)

Exclusion criteria

  • History of taking palbociclib (Ibrance)
  • Patients whose caregivers coordinate their health care

Treatment and study plan

Paper Drug Diary

Other

Participants will receive and use a paper Drug Diary and a paper medication calendar.

OhMD APP

Other

Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication

Other names: Unidirectional text messaging

Primary outcomes

  1. Accuracy rate of medication self-administration

    Time frame: Up to 1 year

    The effectiveness of a mobile technology intervention by calculating the proportion of the number of days that the participant accurately self-administers the medication divided by the number of days the medication should have been taken

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Official study title

Oral Self-Management of Palbociclib (Ibrance®) Using Mobile Technology

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jan 2, 2020
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.